A Snapshot of the NGS Market — User Views
News Aug 21, 2013
The survey was designed to investigate current trends in NGS usage and determine future demands; to aid Oxford Gene Technology (OGT) in continuing to deliver high-quality, up-to-date services and provide insightful, relevant customer resources. The company received 596 responses from its worldwide database of contacts and donated to the UK charity DEBRA (for the genetic skin blistering condition Epidermolysis Bullosa) for each completed survey.
Responses on the most popular research areas for NGS and choice of methods uncovered a trend towards cost-effective, high-resolution targeted resequencing techniques over whole genome sequencing, with the Illumina platform identified as the leading technology. Cancer and rare disease are the most popular research areas for using NGS, supporting the use of targeted approaches which enable more accurate detection of rare variants.
Challenges in bioinformatics were found to be one of the biggest barriers to NGS implementation, which may explain why over a third of investigators choose to outsource data analysis. Supporting this finding, data quality and bioinformatics expertise are cited in the top three essential factors when choosing an NGS service provider.
Further insights into the use of NGS for clinical tests, preferred NGS methods, and demands on service providers are also presented. Download the full results here.
The survey adds to a growing portfolio of informative resources from OGT on NGS, including a recent whitepaper on choosing the right NGS method and a free-to-download demo version of their innovative and easy to use Genefficiency™ NGS reporting software.
Download the survey results or see below for more information on OGT’s Genefficiency services.
Genes Can Influence the Mutation, Activity of Nearby GenesNews
Study shows that a gene’s neighborhood can influence whether and how the activity of a gene changes.READ MORE
Acquisition Sees Agilent Gain Powerful NGS IP PortfolioNews
Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
International Conference on Genomics and Pharmacogenomics
Jul 18 - Jul 19, 2018
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018